Update on active specific immunotherapy with melanoma vaccines

Although a randomized clinical trial has yet to show a statistically significant improvement in the survival of patients receiving vaccine therapy for malignant melanoma, several studies have shown enhanced survival of patients developing an immune response to a melanoma vaccine. The knowledge and t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 1997-09, Vol.66 (1), p.55-64
Main Authors: Conforti, Arnold M., Ollila, David W., Kelley, Mark C., Gammon, Guy, Morton, Donald L.
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - therapeutic use
antigen
Antigens, Neoplasm - therapeutic use
Antineoplastic agents
autologous/allogeneic vaccines
Biological and medical sciences
Cancer Vaccines - therapeutic use
Humans
humoral/cellular immunity
Immunity, Cellular
immunomodulation
Immunotherapy
Immunotherapy, Active - trends
Lymph Node Excision
Medical sciences
Melanoma - immunology
Melanoma - surgery
Melanoma - therapy
Melanoma-Specific Antigens
Neoplasm Proteins - administration & dosage
Neoplasm Proteins - therapeutic use
Pharmacology. Drug treatments
Viral Vaccines - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although a randomized clinical trial has yet to show a statistically significant improvement in the survival of patients receiving vaccine therapy for malignant melanoma, several studies have shown enhanced survival of patients developing an immune response to a melanoma vaccine. The knowledge and techniques of modern molecular biology and immunology suggest multiple strategies to augment this response. The challenge of immunotherapy research is to determine which combination of approaches leads to a favorable clinical response and how to monitor that response effectively. This review identifies components of a successful vaccine, discusses new ways to modulate and stimulate the immune system, and summarizes some of the more interesting clinical trials of melanoma vaccine immunotherapy. J. Surg. Oncol. 1997;66:55–64. © 1997 Wiley‐Liss, Inc.
ISSN:0022-4790
1096-9098
DOI:10.1002/(SICI)1096-9098(199709)66:1<55::AID-JSO12>3.0.CO;2-N